Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accounts Payables: 2020-2024

Historic Accounts Payables for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $14.2 million.

  • Arcutis Biotherapeutics' Accounts Payables fell 70.01% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 70.01%. This contributed to the annual value of $14.2 million for FY2024, which is 18.58% up from last year.
  • According to the latest figures from FY2024, Arcutis Biotherapeutics' Accounts Payables is $14.2 million, which was up 18.58% from $12.0 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Accounts Payables ranged from a high of $14.2 million in FY2024 and a low of $7.1 million during FY2020.
  • In the last 3 years, Arcutis Biotherapeutics' Accounts Payables had a median value of $12.0 million in 2023 and averaged $11.7 million.
  • Data for Arcutis Biotherapeutics' Accounts Payables shows a peak YoY spiked of 35.86% (in 2023) over the last 5 years.
  • Arcutis Biotherapeutics' Accounts Payables (Yearly) stood at $7.1 million in 2020, then rose by 2.98% to $7.4 million in 2021, then grew by 20.05% to $8.8 million in 2022, then surged by 35.86% to $12.0 million in 2023, then increased by 18.58% to $14.2 million in 2024.